<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00421954</url>
  </required_header>
  <id_info>
    <org_study_id># 5239</org_study_id>
    <nct_id>NCT00421954</nct_id>
  </id_info>
  <brief_title>Open-label Ziprasidone Study for Psychosis Treatment in Adolescents</brief_title>
  <official_title>Open-label Feasibility Study for the Treatment of Psychotic Adolescents With Ziprasidone in the Inpatient and Day Hospital Settings</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York State Psychiatric Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>New York State Psychiatric Institute</source>
  <brief_summary>
    <textblock>
      This open-label study will assess the medication Geodon速 (Ziprasidone) in pediatric patients,&#xD;
      aged 13-17, diagnosed with psychotic disorder. Eligible adolescents will receive Geodon速 for&#xD;
      7 weeks and stay at the NYSPI Children's Day Unit (CDU) during the day. If clinically&#xD;
      appropriate, they may also stay at the New York State Psychiatric Institute (NYSPI)&#xD;
      Schizophrenia Research Unit (SRU) inpatient facility.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is an open-label assessment of the feasibility of treating adolescents with&#xD;
      psychotic disorders (schizophreniform disorder, schizoaffective disorder, psychosis not&#xD;
      otherwise specified [NOS], major depressive disorder with psychotic features, and bipolar&#xD;
      disorder with psychotic features) in an inpatient and day hospital setting with ziprasidone&#xD;
      (Geodon). Ziprasidone is a second-generation antipsychotic (SGA) that is FDA-approved for the&#xD;
      treatment of schizophrenia and for the treatment of the manic phase of bipolar disorder in&#xD;
      adults. It is also used clinically in the treatment of psychotic disorders in children,&#xD;
      adolescents and adults. This protocol will help to elucidate the feasibility of studying the&#xD;
      treatment of psychotic disorders with ziprasidone in adolescents 13-17 years and help&#xD;
      facilitate the further study of the treatment of psychosis with novel agents that have a&#xD;
      favorable side effect and weight gain profile.&#xD;
&#xD;
      The duration of the study can be up to 7 weeks. Depending on the level of symptom severity&#xD;
      patients will be managed on either the Schizophrenia Research Unit (SRU) (GAS&lt;35, CGI-S&gt;5),&#xD;
      or the Children's Day Unit (CDU) of the NYSPI. The seven weeks would encompass a 3 day period&#xD;
      at the beginning of the study including time for screening and reviewing lab results. Over a&#xD;
      period of one to two weeks patients will be titrated up to 120 mg/day (80 mg for patients&#xD;
      under 45kg), and, if necessary, cross tapered off of another SGA that had not been working&#xD;
      successfully. Subjects who do not respond to the medication after 1 week at the target dose&#xD;
      will be discontinued from the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2006</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Weight Gain and Other Side Effects</measure>
    <time_frame>couple of months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Schizophreniform Disorder</condition>
  <condition>Schizoaffective Disorder</condition>
  <condition>Psychosis</condition>
  <condition>Depressive Disorder, Major</condition>
  <condition>Bipolar Disorder</condition>
  <arm_group>
    <arm_group_label>Ziprasidone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ziprasidone</intervention_name>
    <description>subjects will use ziprasidone</description>
    <arm_group_label>Ziprasidone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Children who meet DSM-IV criteria for the following psychotic disorders:&#xD;
             schizophreniform disorder, schizoaffective disorder, psychosis NOS, major depressive&#xD;
             disorder with psychotic features, and bipolar disorder with psychotic features.&#xD;
&#xD;
          2. Children with an IQ of at least 70.&#xD;
&#xD;
          3. Children who are in good physical health.&#xD;
&#xD;
          4. The parent/guardian of the child must be willing to attend all study visits.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Children who are currently receiving an effective treatment without detrimental side&#xD;
             effects.&#xD;
&#xD;
          2. Children who are allergic to Geodon速.&#xD;
&#xD;
          3. Children who have previously failed to respond to an adequate trial of Geodon速.&#xD;
&#xD;
          4. Females who are pregnant or breast-feeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lawrence A Maayan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NYSPI</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>NYSPI</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <study_first_submitted>January 12, 2007</study_first_submitted>
  <study_first_submitted_qc>January 12, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 15, 2007</study_first_posted>
  <results_first_submitted>January 12, 2017</results_first_submitted>
  <results_first_submitted_qc>January 12, 2017</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 13, 2017</results_first_posted>
  <last_update_submitted>January 12, 2017</last_update_submitted>
  <last_update_submitted_qc>January 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>psychosis NOS</keyword>
  <keyword>MDD w/ psychotic features</keyword>
  <keyword>bipolar disorder w. psychotic features</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
    <mesh_term>Mental Disorders</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ziprasidone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>P.I. has left the institution and NYSPI has no access to the data. Results will not be analyzed or presented.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Ziprasidone</title>
          <description>Ziprasidone: subjects will use ziprasidone</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>P.I. has left the institution and NYSPI has no access to the data. Results will not be analyzed or presented.</population>
      <group_list>
        <group group_id="B1">
          <title>Ziprasidone</title>
          <description>Ziprasidone: subjects will use ziprasidone</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="0"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
        </measure>
        <measure>
          <title>Gender</title>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                </category>
                <category>
                  <title>Male</title>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <class_list>
            <class>
              <title>United States</title>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Weight Gain and Other Side Effects</title>
        <time_frame>couple of months</time_frame>
        <population>P.I. has left the institution and NYSPI has no access to the data. Results will not be analyzed or presented.</population>
        <group_list>
          <group group_id="O1">
            <title>Ziprasidone</title>
            <description>Ziprasidone: subjects will use ziprasidone</description>
          </group>
        </group_list>
        <measure>
          <title>Weight Gain and Other Side Effects</title>
          <population>P.I. has left the institution and NYSPI has no access to the data. Results will not be analyzed or presented.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>P.I. has left the institution and NYSPI has no access to the data. Results will not be analyzed or presented.</desc>
      <group_list>
        <group group_id="E1">
          <title>Ziprasidone</title>
          <description>Ziprasidone: subjects will use ziprasidone</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Linda Sherman</name_or_title>
      <organization>New York State Psychiatric Institute</organization>
      <phone>(646) 774-7158</phone>
      <email>lsherma@nyspi.columbia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

